Abstract:
:Coronary heart disease is the major cause of morbidity and mortality in industrialized countries, and its prevalence is predicted to grow as the population ages. Current drugs for chronic stable angina (such as beta-blockers, calcium-channel blockers, long- and short-acting nitrates, and potassium-channel activators) are often effective, either as monotherapy or in combination, but side effects and contraindications may limit their use. The "I(f)" (for "funny") channel, discovered in 1979, is expressed mainly in the membrane of pacemaker cells present in the sinus node, the atrioventricular node, the ventricular conduction pathways, and ventricular myocytes. By determining the slope of diastolic depolarization, which in turn controls action potential frequency, it is a key determinant of heart rate and so provides a new therapeutic target for controlling angina symptoms. A new antiangina drug, ivabradine, has been developed and licensed for clinical use. It exclusively reduces the heart rate by selectively blocking the I(f) channel of the sino-atrial node. As clinical trials have shown it to be remarkably well-tolerated, ivabradine offers an alternative for patients who cannot take, or are intolerant of, beta blockade. This review provides an insight into this new agent, its historical background, mechanism of action, and pathophysiologic basis, and provides up-to-date evidence-based information on its optimum use in stable angina.
journal_name
Adv Therjournal_title
Advances in therapyauthors
Prasad UK,Gray D,Purcell Hdoi
10.1007/s12325-009-0005-xsubject
Has Abstractpub_date
2009-02-01 00:00:00pages
127-37issue
2eissn
0741-238Xissn
1865-8652journal_volume
26pub_type
杂志文章,评审abstract:BACKGROUND:There have been few large studies that have analyzed the effect of professional (masked) continuous glucose monitoring (P-CGM) on glycemic control in patients with type 2 diabetes (T2DM) who were on a broad spectrum of baseline therapies. METHODS:We performed a retrospective, blinded evaluation of glycemic ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-017-0576-x
更新日期:2017-08-01 00:00:00
abstract::In order for the global healthcare system to remain sustainable, healthcare spending needs to be reduced, and self-treating certain conditions under the guidance of a pharmacist provides a means of accomplishing this goal. This article was developed to describe global healthcare trends affecting self-care with a speci...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-016-0395-5
更新日期:2016-10-01 00:00:00
abstract:INTRODUCTION:Anti-vascular endothelial growth factor therapy is the standard of care for neovascular age-related macular degeneration (nAMD). The dosage of two licensed agents, ranibizumab and aflibercept, was established through clinical trials; however, it is unclear if either agent is administered as recommended in ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-017-0624-6
更新日期:2017-12-01 00:00:00
abstract:INTRODUCTION:The aim of this study was to investigate whether the efficacy of liraglutide observed in randomized controlled trials translates into therapeutic benefits in the French population during routine clinical practice. METHODS:This observational, prospective, multicenter study included 3152 adults with type 2 ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-015-0245-x
更新日期:2015-09-01 00:00:00
abstract:INTRODUCTION:Respiratory tract infections are common, and these infections occur frequently in children, susceptible adults, and older persons. The risk for recurrences and complications relates not only to the presence of viruses but also to immune function. Therefore, modulation of the immune system and antiviral int...
journal_title:Advances in therapy
pub_type: 杂志文章,多中心研究
doi:10.1007/s12325-015-0194-4
更新日期:2015-03-01 00:00:00
abstract::In the original article. The third author name is incorrect. The correct name is Nicholas J. Leeper. ...
journal_title:Advances in therapy
pub_type: 已发布勘误
doi:10.1007/s12325-020-01220-5
更新日期:2020-02-01 00:00:00
abstract:INTRODUCTION:Rivastigmine is a cholinesterase inhibitor, approved for the treatment of mild-to-moderate dementia of Alzheimer's type. This study assessed the short- and long-term effectiveness and safety of rivastigmine in patients with mild-to-moderate Alzheimer's disease (AD) in a real-world clinical setting in Taiwa...
journal_title:Advances in therapy
pub_type: 杂志文章,多中心研究
doi:10.1007/s12325-019-00939-0
更新日期:2019-06-01 00:00:00
abstract::In this double-blind, randomized, placebo-controlled, prospective study, the clinical efficacy and tolerability of oral Hypericum extract STW 3-VI (Laif) 900 mg once daily was compared with that of placebo. A total of 140 outpatients (94 women; 46 men) with moderate depressive disorders and a 17-item Hamilton Depressi...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1007/BF02850158
更新日期:2004-07-01 00:00:00
abstract::Nateglinide is an oral antidiabetic medication that acts through rapid, short-term stimulation of insulin production. This study was undertaken to identify the incidence and nature of adverse effects of nateglinide and to assess its efficacy in clinical practice. Patients (n = 3254) were recruited from 606 centers in ...
journal_title:Advances in therapy
pub_type: 杂志文章,多中心研究
doi:10.1007/BF02849871
更新日期:2005-09-01 00:00:00
abstract:PURPOSE:To compare the efficacy and safety of combined cataract extraction and either excisional goniotomy performed with the Kahook Dual Blade (KDB; phaco-KDB group) or single iStent trabecular bypass implantation (phaco-iStent group) in eyes with mild to moderate glaucoma and visually significant cataract. METHODS:T...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-01025-1
更新日期:2019-09-01 00:00:00
abstract::In an open-label 12-week study, the safety and efficacy of bimatoprost 0.03% was evaluated in 55 patients with open-angle glaucoma or ocular hypertension inadequately controlled by topical beta-blocker monotherapy. Patients discontinued their topical beta-blocker therapy at the baseline visit and began bimatoprost mon...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章
doi:10.1007/BF02850101
更新日期:2004-11-01 00:00:00
abstract:INTRODUCTION:The purpose of the study was to conduct a cost-effectiveness analysis and budget impact analysis comparing lopinavir with ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) for antiretroviral-naïve patients with a baseline CD4+ T-cell distribution and total cholesterol (TC) profile as reported in th...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-008-0141-8
更新日期:2009-02-01 00:00:00
abstract:INTRODUCTION:Claims data (IBM MarketScan Commercial and MarketScan Medicare Supplemental databases) from June 30, 2011 to September 30, 2017 were used to evaluate the cost impact of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in this retrospective cohort study. METHODS:The p...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01283-4
更新日期:2020-04-01 00:00:00
abstract:INTRODUCTION:Although chronic opioid therapy is usually initiated using short-acting opioids, many patients with chronic pain are subsequently converted to long-acting and extended-release preparations. In clinical practice, optimal management requires careful individualization of dosage in order to achieve an appropri...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-012-0051-7
更新日期:2012-10-01 00:00:00
abstract:INTRODUCTION:Real-world data are sparse on longitudinal associations of opioid use with pain interference with activities (PIA) and daily function with osteoarthritis (OA) in the USA. METHODS:Data from the 2010-2015 Medical Expenditure Panel Surveys were analyzed for community-dwelling adults with OA. Opioid use patte...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-01200-4
更新日期:2020-02-01 00:00:00
abstract:OBJECTIVE:Examine outcomes and costs of patients with persistent asthma who initiated treatment with beclomethasone dipropionate hydrofluoroalkane (BDP-HFA) or fluticasone propionate (FP). METHODS:MedStat's Commercial Claims and Encounters database (July 1, 2002-June 30, 2007) was utilized. Patients (n=13,968) were in...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-009-0056-z
更新日期:2009-08-01 00:00:00
abstract:INTRODUCTION:Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. It is vitally important to predict prognosis and restrict unnecessary adjuvant treatments for patients with ACC. This study aims to confirm the prognostic value of Ki-67 and provide a prognostic evaluation on ACC after primary surgery...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-01050-0
更新日期:2019-10-01 00:00:00
abstract::Nonketotic hyperosmolar coma (NHC) is characterized by severe hyperglycemia; absence of, or only slight ketosis; nonketotic acidosis; severe dehydration; depressed sensorium or frank coma; and various neurologic signs. This condition is uncommon in type 1 diabetes. Because of little or no osmotic diuresis in patients ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/BF02849861
更新日期:2005-09-01 00:00:00
abstract::This study was conducted to determine the reasons for the choice of self-prescribed laxatives and to acquire information on how they were used and tolerated. From November 1999 to February 2000, 70 pharmacies, uniformly located throughout the Campania region of southern Italy, distributed a questionnaire to purchasers...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/BF02850360
更新日期:2002-09-01 00:00:00
abstract:INTRODUCTION:This clinical study aimed to investigate the effect of brinzolamide, a topical carbonic anhydrase inhibitor, on corneal endothelial cells (CECs) in patients with glaucoma using a follow-up clinical study design. METHODS:Patients with primary open-angle glaucoma or ocular hypertension were administrated an...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章
doi:10.1007/s12325-016-0373-y
更新日期:2016-08-01 00:00:00
abstract:INTRODUCTION:Subsequent lines of subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment may be well motivated in the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)-collectively named inflammatory arthritis (IA). However, the costs associated with swit...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01425-8
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND:The OPTIMA© (MSD, Courbevoie, France) questionnaire was developed to promote shared decisions and the set-up of specific micro-objectives in clinical practice by optimizing communication between type 2 diabetes (T2DM) patients and their physicians. The present study aimed to assess OPTIMA in clinical practic...
journal_title:Advances in therapy
pub_type: 杂志文章,多中心研究
doi:10.1007/s12325-016-0341-6
更新日期:2016-06-01 00:00:00
abstract:INTRODUCTION:Wet age-related macular degeneration (AMD) is a chronic eye condition that causes severe deterioration of vision and even blindness. Current wet AMD treatment in the UK involves the vascular endothelial growth factor inhibitors ranibizumab and aflibercept. Patients with wet AMD require frequent and long-te...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-016-0367-9
更新日期:2016-09-01 00:00:00
abstract::In a multicenter, open-label evaluation, 1098 patients with ocular itching and a history of perennial or seasonal allergic conjunctivitis instilled one drop of nedocromil sodium 2% twice daily in each eye. Ocular symptoms, signs, and global improvement were assessed at baseline and 1 month; satisfaction scores, qualit...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1007/BF02850056
更新日期:2002-03-01 00:00:00
abstract:INTRODUCTION:Comparisons between brand and biosimilar basal insulin in hospitalized patients are lacking. We aimed to compare the efficacy and safety of brand insulin glargine vs. biosimilar insulin glargine in non-critical hospitalized patients with type 2 diabetes mellitus (T2DM). METHODS:This retrospective study wa...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-00922-9
更新日期:2019-05-01 00:00:00
abstract:INTRODUCTION:This study of UK patients examines clinical, health-related quality of life (HRQOL) and economic outcomes associated with iron chelation therapy (ICT). Desferrioxamine (DFO) (Desferal; Novartis, Switzerland) and Deferiprone (Ferriprox; Apotex, Canada) are ICTs used to treat iron overload. DFO requires 8-to...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-008-0085-z
更新日期:2008-08-01 00:00:00
abstract::In the original article, under the "Access to treatment" heading. ...
journal_title:Advances in therapy
pub_type: 已发布勘误
doi:10.1007/s12325-020-01488-7
更新日期:2020-11-01 00:00:00
abstract:INTRODUCTION:Alcohol dependence represents a severe pathological disorder associated with a significant rate of morbidity and mortality. To date, limited pharmacological agents exist to treat this disorder, and there is a growing interest for new therapies. In this context, pregabalin represents a promising strategy. P...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-012-0061-5
更新日期:2012-11-01 00:00:00
abstract:INTRODUCTION:Well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are often slow-growing, and some patients with unresectable, asymptomatic, non-functioning tumors may face the choice between watchful waiting (WW), or somatostatin analogues (SSA) to delay progression. We developed ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-017-0653-1
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:Mutation of human receptor tyrosine kinase epidermal growth factor receptor-2 (HER2) is a rare event, found in approximately 1% non-small cell lung cancers (NSCLC). The objective was to investigate the clinical characteristics and management of HER2-mutated NSCLCs in a real-life setting. METHODS:This multic...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-01001-9
更新日期:2019-08-01 00:00:00